Pernix Therapeutics Holdings (NYSE:PTX) was downgraded by equities research analysts at Guggenheim from a “buy” rating to a “neutral” rating in a research note issued to investors on Wednesday, TheFlyOnTheWall.com reports.
Pernix Therapeutics Holdings (NYSE:PTX) opened at 2.19 on Wednesday. Pernix Therapeutics Holdings has a 52 week low of $1.68 and a 52 week high of $8.70. The stock has a 50-day moving average of $2.36 and a 200-day moving average of $3.12. The company’s market cap is $81.3 million.
Pernix Therapeutics Holdings (NYSE:PTX) last announced its earnings results on Tuesday, November 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by $0.04. The company had revenue of $18.30 million for the quarter, compared to the consensus estimate of $23.06 million. During the same quarter in the previous year, the company posted ($0.03) earnings per share. On average, analysts predict that Pernix Therapeutics Holdings will post $-0.52 earnings per share for the current fiscal year.
In other Pernix Therapeutics Holdings news, major shareholder Cooper C. Collins sold 90,000 shares of Pernix Therapeutics Holdings stock on the open market in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $2.01, for a total transaction of $180,900.00. The transaction was disclosed in a document filed with the SEC, which is available at this link. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.
Several other analysts have also recently commented on the stock. Analysts at Cantor Fitzgerald upgraded shares of Pernix Therapeutics Holdings from a “sell” rating to a “hold” rating in a research note to investors on Wednesday. Separately, analysts at Stifel Nicolaus downgraded shares of Pernix Therapeutics Holdings from a “buy” rating to a “hold” rating in a research note to investors on Tuesday. Finally, analysts at Zacks upgraded shares of Pernix Therapeutics Holdings from an “underperform” rating to a “neutral” rating in a research note to investors on Thursday, November 7th. They now have a $2.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and two have given a buy rating to the stock. Pernix Therapeutics Holdings currently has an average rating of “Hold” and a consensus target price of $4.25.
Pernix Therapeutics Holdings, Inc (NYSE:PTX) is a specialty pharmaceutical company focused on the sales, marketing and development of branded and generic pharmaceutical products for pediatric and adult indications in a range of therapeutic areas.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.